RNAC Stock Analysis: Buy, Sell, or Hold?
RNAC - Cartesian Therapeutics, Inc. Common Stock
$9.64
-0.54 (-5.30%)
▼
5d:
+6.52%
30d:
+42.81%
90d:
+58.81%
HOLD
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When RNAC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RNAC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: RNAC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: RNAC is currently trading at $9.64, which is considered extended relative to its 30-day fair value range of $6.20 to $9.01.
Technical Outlook: Technically, RNAC is showing sideways momentum. The price is approaching resistance at $9.33. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: RNAC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.57 (+258.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RNAC is showing sideways momentum. The price is approaching resistance at $9.33. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: RNAC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.57 (+258.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.20 -
$9.01
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BEARISH: Price extended above range (+7.0% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.3%)
- BULLISH: Trading 258.6% below Wall St target ($34.57)
Trading Range Analysis
30-Day Trading Range
$6.20 -
$9.01
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.77
Resistance Level
$9.33
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.60
Wall Street Target
$34.57
(+258.6%)
Revenue Growth (YoY)
-92.9%
Earnings Growth (YoY)
-7.4%
Share & Embed Analysis
Last updated: June 24, 2026 5:57 PM ET
Data refreshes hourly during market hours. Next update: 6:57 PM
Data refreshes hourly during market hours. Next update: 6:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNAC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Blaine Davis
SELL
10591 shares
2026-01-06
Milos Miljkovic
SELL
3573 shares
2026-01-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 58 HOLD |
